Patent applications and USPTO patent grants for LAVA THERAPEUTICS B.V..The latest application filed is for "novel cd40-binding antibodies".
Patent | Date |
---|---|
Novel Cd40-binding Antibodies App 20220135694 - VAN DER VLIET; Johannes Jelle ;   et al. | 2022-05-05 |
Dual Acting Cd1d Immunoglobulin App 20220111043 - VAN DER VLIET; Johannes Jelle ;   et al. | 2022-04-14 |
Novel Bispecific Antibodies For Use In The Treatment Of Hematological Malignancies App 20210371525 - DE WEERDT; Iris ;   et al. | 2021-12-02 |
Single Domain Antibodies Targeting Cd1d App 20200115450 - VAN DER VLIET; Johannes Jelle ;   et al. | 2020-04-16 |
Immunoglobulins binding human V.gamma.9 V.delta.2 T cell receptors Grant 10,501,540 - Van Der Vliet , et al. Dec | 2019-12-10 |
Single domain antibodies targeting CD1d Grant 10,501,541 - Van Der Vliet , et al. Dec | 2019-12-10 |
Immunoglobulins binding human Vγ9Vδ2 T cell receptors App 20190263908 - VAN DER VLIET; Johannes Jelle ;   et al. | 2019-08-29 |
Single Domain Antibodies Targeting Cd1d App 20180142020 - VAN DER VLIET; Johannes Jelle ;   et al. | 2018-05-24 |
SEC | 1840748 | LAVA Therapeutics BV of NETHERLANDS |
SEC | 0001840748 | LAVA Therapeutics BV of NETHERLANDS |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.